Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple

    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 2102-ONC-102 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone 3052438173

    IRB: 20180721

    SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System,Pancreas,Bones and Joints,Soft Tissue

    Sponsor: FORMA

    Enrolling Sites:

    Sylvester

    Title:

    2102-ONC-102: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation

    Eligibility Criteria - NCT03684811 *This information has been extracted from " www.clinicaltrials.gov"

  • AFPc332T - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:

    IRB: 20160692

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Liver

    Sponsor: Adaptimmune

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Open Label, Clinical Trial Evaluating the Safety and Anti-tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha-fetoprotein (AFPc332T) in HLA-A2 Positive Subjects with Advanced epatocellular Carcinoma (HCC)

    Eligibility Criteria - NCT03132792 *This information has been extracted from " www.clinicaltrials.gov"

  • MK7902-002 - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20181018

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Liver

    Sponsor: MERCK SHARP & DOHME

    Enrolling Sites:

    Sylvester

    Title:

    002-00 (E7080-G000-311) : Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination with Pembrolizumab (MK-3475) Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma (LEAP-002)

    Eligibility Criteria - NCT03713593 *This information has been extracted from " www.clinicaltrials.gov"

  • TACE - Feun, Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Carla Montoya
    RCphone 3052431139

    IRB: 20190406

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Liver

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma

    Eligibility Criteria - NCT03778957 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190633 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20190633

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Pancreas

    Sponsor: AngioDynamics, Inc.

    Enrolling Sites:

    Sylvester

    Title:

    A Randomized, Multicenter, Controlled, Unblinded Study to Assess the Safety and Efficacy of the NanoKnifeŽ System for the Ablation of Unresectable Stage 3 Pancreatic Adenocarcinoma

    Eligibility Criteria - NCT03899636 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190822 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20190822

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Ovary,Prostate,Stomach,Colon,Rectum,Pancreas,Other Digestive Organ,Lung,Melanoma, skin

    Sponsor: NGM BIOPHARMACEUTICALS

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Dose-Escalation Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy

    Eligibility Criteria - NCT04068896 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    Coordinator:

    IRB: 20191076

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin

    Sponsor: EISAI

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101

    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • 20160023 - Kobetz Erin

  • Investigator:
    Erin Kobetz
    RCname Email

    Coordinator:

    IRB: 20160023

    SDG: Population Sciences
    Disease Site(s):

    Cervix Uteri,Other Hematopoietic,Colon,Rectum,Liver

    Sponsor: NIMHD

    Enrolling Sites:

    Community Clinics
    Sylvester

    Title:

    Increasing Uptake of Evidence Based Screening Services through a CHW led multi modality intervention: South Florida Center for Reducing Health Disparities.

    Eligibility Criteria - NCT02970136 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • TTX-030-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone 3052435486

    IRB: 20181017

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Colon,Pancreas

    Sponsor: TTH

    Enrolling Sites:

    Sylvester

    Title:

    TTX-030-001 : Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination with Pembrolizumab or Chemotherapy inPatients with Lymphoma or Solid Tumor Malignancies

    Eligibility Criteria - NCT03884556 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-444-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190073

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate,Bladder,Kidney,Liver

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-444-001: A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

    Eligibility Criteria - NCT02655822 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"